Skip to main content
. 2020 May 22;10:8532. doi: 10.1038/s41598-020-65640-7

Figure 5.

Figure 5

Uptake of EVs from RAS-driven cancer cells triggers TP53 expression in endothelial cells. (A) Untreated HUVEC. (B) HUVEC treated with IEC-18 EVs. C. HUVEC treated with RAS-3 EVs (DAPI – blue; anti-TP53 – red).